Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK Aims Flonase Sensimist To Counter Generic Nasal Allergy Competition

Executive Summary

GlaxoSmithKline Flonase Sensimist Allergy Relief could help fend off private label competition in the intranasal corticosteroid category, the firm says. Despite a 19% drop in sales of the original Flonase OTC in the fourth quarter, US consumer health care sales grew 5% to $2.2bn on a reported basis in 2016.

Advertisement

Related Content

Perrigo’s Outgoing CEO Advocates OTC Switches, Starting With Statins
Consumer Business Reliable And Right At Home At GlaxoSmithKline
Glaxo’s Parodontax Brings Bleeding Gums Claim To US Toothpaste Battle
Glaxo’s Parodontax Brings Bleeding Gums Claim To US Toothpaste Battle
GSK Consumer Leaving Costa Rica: Consumer Health News Roundup
GSK Management Shake Up Ahead Of New CEO Sees Hussain Out, AZ's Miels In
GSK's Flonase Sensimist (Veramyst) Switches Name On Way To OTC
Fluticasone Spray Competition Grows With Perrigo Launch Of West-Ward Product
Glaxo In Charge, And The World Is GSK/Novartis Consumer Product JV’s Oyster

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS119998

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel